Table 1.
Outcomes related to secondary hepatic resection in patients treated with oxaliplatin-based chemotherapy
| Study | n | Regimen | Response rate (%) | Resection rate (%) | R0 rate (%) | MS (mo) |
| Unselected populations | ||||||
| GERCOR[14] | 111 | FOLFOX6 | 54.0 | 22.0 | 13.0 | NYR |
| Tournigand et al[24] | 311 | FOLFOX4 | 58.5 | 17.7 | 11.3 | 38.9 |
| Tournigand et al[24] | 309 | FOLFOX71 | 59.2 | 15.2 | 9.4 | 43.0 |
| Colucci et al[23] | 182 | FOLFOX4 | 34.0 | 4.4 | NR | NR |
| Liver metastases only | ||||||
| Alberts et al[25] | 44 | FOLFOX4 | 60.0 | 40.0 | 33.3 | NR |
1
FOLFOX7 × 6 cycles, followed by treatment without oxaliplatin × 12 cycles, followed by FOLFOX7 until PD. MS: Median survival in resected patients; FOLFOX: Oxaliplatin plus infusional 5-fluorouracil/leucovorin (5-FU/LV); NYR: Not yet reached; NR: Not reported.